Anticoagulation for Valvular Heart Disease | 合法醫療器材資訊網

2015年5月18日—Therefore,theACCPrecommendsVKAtherapywithatargetINRof2.5(range2.0to3.0)formechanicalaorticvalvesandtargetINRof3.0( ...

Valvular heart disease (VHD) is a common contributor to cardiac morbidity and mortality.1-3 Current data estimate the overall prevalence of VHD in the United States to be 2.5%, with prevalence estimates in those over the age of 75 to be as high as 13.3%.4

Surgical repair of VHD with either a mechanical or bioprosthetic valve is a common solution with ever-improving operative outcomes.5,6 Observational data indicate a steady increase in the use of bioprosthetic valves, with a concurrent decrease in the use of mechanical prostheses.5,6 This may be attributable to the advancing technology in bioprosthetic device development, and the increasing rate of valve replacement surgery in the elderly, in whom bioprosthetic devices are preferred.7

Thrombotic and embolic complications and anticoagulation-related bleeding are by far the most prevalent contributors to morbidi...